Zobrazeno 101 - 110
of 199
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Melissa S. Thebeau, Geoffrey T. Gibney, Ragini R. Kudchadkar, Jeffrey S. Weber, Cabell Eysmans, H. David Inzunza, Maria P. Czupryn, Leticia Tetteh, Kate Fisher, Ronald C. DeConti, Alberto J Martinez, Christine Horak, Michael J. Schell, Allison Richards, Ibrahim Younos, Bin Yu
Purpose: The anti-programmed death-1 (PD-1) antibody nivolumab (BMS-936558) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected stage IIIC and IV melanoma patients. Exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed3763189ea926d47974a58f0920f2f
https://europepmc.org/articles/PMC4620684/
https://europepmc.org/articles/PMC4620684/
Autor:
Jacques Galipeau, Jiusheng Deng, Andrea Pennati, Ragini R. Kudchadkar, David H. Lawson, Shala Yuan
Publikováno v:
Journal for Immunotherapy of Cancer
Melanoma is the most dangerous type of skin cancer and one of the fastest growing cancers in the USA. Immunotherapy, by enhancing patient's immune system, has become an attractive approach for melanoma treatment due to the rapid drug resistance to ch
Autor:
Michael S. Gordon, Gerald Edelman, Douglas O. Clary, Johanna C. Bendell, Ragini R. Kudchadkar, Stuart Johnston, Mark A. Dickson, Gary K. Schwartz, Patricia LoRusso
Publikováno v:
Investigational new drugs. 33(2)
Background XL281 is a potent and selective inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in multiple xenograft models. Mutations in KRAS or BRAF can activate the RAF/MEK/ERK pathway in human tumors and may confer sensitivity
Autor:
Evan J. Lipson, Nageatte Ibrahim, Janice M. Mehnert, Kristen Spencer, Keisuke Shirai, Heddy Bartell, Ragini R. Kudchadkar, David H. Lawson, Jason J. Luke, Sowmya Ravi, Mary Ruisi, Ngoc Thi Gunter, John A. Thompson
Publikováno v:
Journal for Immunotherapy of Cancer
Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melanoma. Ipilimumab is associated with potenti
Autor:
Geoffrey H. Smith, Rathi N. Pillai, Linsheng Zhang, Michael R. Rossi, Kevin E. Fisher, Stewart G. Neill, Ragini R. Kudchadkar
Publikováno v:
Current problems in cancer. 38(5)
For many physicians, genetic testing in any form falls within the category of esoteric testing. The concept that gene mutations or copy number abnormalities are only understood by a limited number of specialists, and that the data may only be relevan
Autor:
Yeung-Chul Mun, J.Y. Tang, Mario E. Lacouture, K. Dawson, J. Guillen, G. Rogers, Aleksandar Sekulic, Thomas Olencki, S. Yoo, Ragini R. Kudchadkar
Publikováno v:
European Journal of Cancer. 51:S679-S680
Autor:
Ragini R. Kudchadkar, L. Lundgren, Suzanne L. Topalian, Elad Sharon, Kim Margolin, W. Sharfman, E. Lipson, S. Reddy, Adil Daud, Shailender Bhatia, Harriet M. Kluger, M. Cheever, Philip Friedlander, E. Shantha, John F. Thompson, Paul Nghiem, Holbrook E Kohrt
Publikováno v:
European Journal of Cancer. 51:S720-S721
Autor:
Ibrahima Soumaoro, Raid Aljumaily, Anthony Gonçalves, Paul Nghiem, Alexander Cao, Suzanne L. Topalian, William C. Spanos, William H. Sharfman, Shangbang Rao, Shailender Bhatia, Antoine Hollebecque, Jose Maria Lopez Picazo, Jean-Pierre Delord, Ana Oaknin, Dirk Schadendorf, Jan de Boer, Uwe M. Martens, Ahmad Awada, Ragini R. Kudchadkar
Publikováno v:
Cancer Research. 77:CT074-CT074
Background: NIVO (anti-PD-1) is approved for the treatment of several cancers including advanced melanoma, but its efficacy in other types of skin cancer has not yet been evaluated. MCC is a rare and aggressive form of skin cancer, with most tumors b
Autor:
Joel Jiang, Rene Gonzalez, Alexandre Avila, Reena Thomas, Ahmad A. Tarhini, Omid Hamid, Stergios J. Moschos, Igor Puzanov, Michael B. Atkins, Ragini R. Kudchadkar, Sheena Demelo, F. Stephen Hodi, Michael A. Postow, Christopher D. Lao, Hussein Abdul-Hassan Tawbi, Nikhil I. Khushalani, Kim Margolin, Marc S. Ernstoff, Alain Algazi, Peter A. Forsyth
Publikováno v:
Journal of Clinical Oncology. 35:9507-9507
9507 Background: Brain metastases (BMts) are a major cause of morbidity/death in MEL. We report the first efficacy data in MEL patients (pts) with BMts who received NIVO+IPI in study CheckMate 204. Methods: In this multicenter US trial (NCT02320058),
Autor:
Danni Yu, Ragini R. Kudchadkar, Robert Wesolowski, Sonya C. Tate, Shande Tang, David Schaer, Richard D. Carvajal, Samuel J. Klempner, Gulam Abbas Manji, John S. Kauh, R. Donald Harvey, Hope S. Rugo, Afshin Dowlati, Omid Hamid
Publikováno v:
Journal of Clinical Oncology. 35:2523-2523
2523 Background: Binding of CSF-1 to the CSF-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macrophages. Intratumoral infiltration with macrophages correlates with increased invasiveness, growth, and immunos